Mouse Oligodendrocyte Differentiation Kit from R&D Systems
Goat Anti-VAP-1 (S-13) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
...atoms at the 3, 3', 4, and 4' positions. It is int...tification of Prostaglandin E2 (PGE2) by GC- or LC...looxygenase products of arachidonic acid and one o... activity influences inflammation, fertility and p...
Site-directed Mutagenesis from Exon BioSystems
Biology Products:(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)MELVILLE, N.Y., Dec. 3 Nikon Corporation, an innovator of advanced optical instruments, announced today that it has signed a licensing agreement with Harvard University granting Nikon the rights to u
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4